Latest & greatest articles for ezetimibe

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on ezetimibe or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on ezetimibe and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for ezetimibe

1. PCSK9 inhibitors and ezetimibe on risk of incident diabetes: systematic review and meta-analysis

PCSK9 inhibitors and ezetimibe on risk of incident diabetes: systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

2. Usefulness of Low-Dose Statin Plus Ezetimibe and/or Nutraceuticals in Patients With Coronary Artery Disease Intolerant to High-Dose Statin Treatment

Usefulness of Low-Dose Statin Plus Ezetimibe and/or Nutraceuticals in Patients With Coronary Artery Disease Intolerant to High-Dose Statin Treatment High-dose statin (HDS) therapy is recommended to reduce low-density lipoprotein cholesterol (LDL-C); however, some patients are unable to tolerate the associated side effects. Nutraceuticals have shown efficacy in lowering LDL-C. The aim of this study was to evaluate whether the combination of low-dose statin (LDS) plus ezetimibe (EZE) or LDS plus

2018 EvidenceUpdates

3. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. (PubMed)

Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. Cardiovascular disease (CVD) remains an important cause of mortality and morbidity, and high levels of blood cholesterol are thought to be the major modifiable risk factors for CVD. The use of statins is the preferred treatment strategy for the prevention of CVD, but some people at high-risk for CVD are intolerant to statin therapy or unable to achieve their treatment goals with the maximal recommended doses (...) of statin. Ezetimibe is a selective cholesterol absorption inhibitor, whether it has a positive effect on CVD events remains uncertain. Results from clinical studies are inconsistent and a thorough evaluation of its efficacy and safety for the prevention of CVD and mortality is necessary.To assess the efficacy and safety of ezetimibe for the prevention of CVD and all-cause mortality.We searched the CENTRAL, MEDLINE, Embase and Web of Science on 27 June 2018, and two clinical trial registry platforms

2018 Cochrane

4. Ezetimibe

Ezetimibe Top results for ezetimibe - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for ezetimibe The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

5. Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) (Full text)

Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) Patients who experience an acute coronary syndrome are at heightened risk of recurrent ischemic events, including stroke. Ezetimibe improved cardiovascular outcomes when added to statin therapy in patients stabilized after acute coronary syndrome. We investigated the efficacy of the addition (...) of ezetimibe to simvastatin for the prevention of stroke and other adverse cardiovascular events in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial), with a focus on patients with a stroke before randomization.Patients who experienced acute coronary syndrome were randomized to a placebo/simvastatin or ezetimibe/simvastatin regimen and followed for a median of 6 years. Treatment efficacy was assessed for the entire population and by subgroups for the first and total (first

2018 EvidenceUpdates PubMed

6. Does the addition of ezetimibe to statins reduce cardiovascular risk? (Full text)

Does the addition of ezetimibe to statins reduce cardiovascular risk? Statins are the mainstay of lipid-lowering therapy nowadays, since they reduce cardiovascular risk when used as primary or secondary prevention. However, only one third of the patients reach the goals established in several guidelines, and even if they do, they keep a risk higher than healthy controls. One of the new lipid-lowering agents is ezetimibe. Searching in Epistemonikos database, which is maintained by screening (...) multiple databases, we identified nine systematic reviews comprising 67 trials overall. We combined the evidence using meta-analysis and generated a summary of findings following the GRADE approach. We concluded adding ezetimibe to statins probably results in little or no difference in overall mortality. It might lead to a small reduction in the risk of myocardial infarction and stroke, but the certainty of the evidence is low.

2017 Medwave PubMed

7. Efficacy and Safety of Alirocumab Versus Ezetimibe Over 2 Years (from ODYSSEY COMBO II) (Full text)

Efficacy and Safety of Alirocumab Versus Ezetimibe Over 2 Years (from ODYSSEY COMBO II) The proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab has been shown to substantially reduce low-density lipoprotein cholesterol (LDL-C). Demonstrating whether efficacy and safety are maintained over a long duration of exposure is vital for clinical decision-making. The COMBO II trial compared the efficacy and safety of alirocumab versus ezetimibe over 2 years. A prespecified first analysis (...) was reported at 52 weeks. Here we report the final end-of-study data (on-treatment) and evaluate post hoc the safety profile with longer versus shorter duration of alirocumab exposure. Patients (n = 720) on maximally tolerated statin dose were treated with alirocumab (75/150 mg every 2 weeks) or ezetimibe (10 mg/day). Overall mean adherence for both treatment groups during the first and second year was >97%. At 2 years, LDL-C was reduced by 49% (alirocumab) versus 17% (ezetimibe; p <0.0001), and LDL-C <70

2017 EvidenceUpdates PubMed

8. Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial (Full text)

Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial To elucidate the effects of intensive LDL-C lowering treatment with a standard dose of statin and ezetimibe in patients with dyslipidaemia and high risk of coronary events, targeting LDL-C less than 70 mg/dL (1.8 mmol/L), compared with standard LDL-C lowering lipid monotherapy targeting less (...) than 100 mg/dL (2.6 mmol/L).The HIJ-PROPER study is a prospective, randomized, open-label trial to assess whether intensive LDL-C lowering with standard-dose pitavastatin plus ezetimibe reduces cardiovascular events more than standard LDL-C lowering with pitavastatin monotherapy in patients with acute coronary syndrome (ACS) and dyslipidaemia. Patients were randomized to intensive lowering (target LDL-C < 70 mg/dL [1.8 mmol/L]; pitavastatin plus ezetimibe) or standard lowering (target LDL-C 90 mg

2017 EvidenceUpdates PubMed

9. Effect on Fasting Serum Glucose Levels of Adding Ezetimibe to Statins in Patients With Nondiabetic Hypercholesterolemia (Full text)

Effect on Fasting Serum Glucose Levels of Adding Ezetimibe to Statins in Patients With Nondiabetic Hypercholesterolemia Statin therapy is associated with a slightly increased risk of developing diabetes mellitus and insulin resistance in patients without diabetes. Ezetimibe combined with statins may be considered for high-risk patients who do not achieve optimal low-density lipoprotein cholesterol lowering on statin monotherapy or who are statin intolerant. Changes in fasting serum glucose (FSG (...) ) levels during ezetimibe, ezetimibe/statin, and statin treatments were assessed using data pooled from clinical trials in hypercholesterolemic and heterozygous familial hypercholesterolemic patients, who were or were not receiving statin therapy. Study types included first-line trials in statin-naive/wash-out patients and second-line add-on and uptitration studies in patients on stable statin therapy. Similar analyses of FSG changes were performed separately for each study type in patients who were

2016 EvidenceUpdates PubMed

10. LIPTRUZET (ezetimibe/atorvastatin), fixed combination of cholesterol-lowering drugs

LIPTRUZET (ezetimibe/atorvastatin), fixed combination of cholesterol-lowering drugs LIPTRUZET SUMMARY CT14103

2016 Haute Autorite de sante

11. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. (Full text)

Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. Muscle-related statin intolerance is reported by 5% to 20% of patients.To identify patients with muscle symptoms confirmed by statin rechallenge and compare lipid-lowering efficacy for 2 nonstatin therapies, ezetimibe and evolocumab.Two-stage randomized clinical trial including 511 adult patients with uncontrolled low-density lipoprotein cholesterol (...) (LDL-C) levels and history of intolerance to 2 or more statins enrolled in 2013 and 2014 globally. Phase A used a 24-week crossover procedure with atorvastatin or placebo to identify patients having symptoms only with atorvastatin but not placebo. In phase B, after a 2-week washout, patients were randomized to ezetimibe or evolocumab for 24 weeks.Phase A: atorvastatin (20 mg) vs placebo. Phase B: randomization 2:1 to subcutaneous evolocumab (420 mg monthly) or oral ezetimibe (10 mg daily).Coprimary

2016 JAMA PubMed

12. Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia

Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia Ezetimibe for treating primary Ezetimibe for treating primary heterozygous-familial and non-familial heterozygous-familial and non-familial h hypercholesterolaemia ypercholesterolaemia T echnology appraisal guidance Published: 24 February 2016 nice.org.uk/guidance/ta385 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our (...) unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia (TA385) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk

2016 National Institute for Health and Clinical Excellence - Technology Appraisals

13. Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP) (Full text)

Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP) Simvastatin, 20mg, plus ezetimibe, 10mg, daily (simvastatin plus ezetimibe) reduced major atherosclerotic events in patients with moderate to severe chronic kidney disease (CKD) in the Study of Heart and Renal Protection (SHARP), but its cost-effectiveness is unknown.Cost-effectiveness of simvastatin plus ezetimibe in SHARP, a randomized controlled (...) trial.9,270 patients with CKD randomly assigned to simvastatin plus ezetimibe versus placebo; participants in categories by 5-year cardiovascular risk (low, <10%; medium, 10%-<20%; or high, ≥20%) and CKD stage (3, 4, 5 not on dialysis, or on dialysis therapy).Assessment during SHARP follow-up from the UK perspective; long-term projections.Simvastatin plus ezetimibe (2015 UK £1.19 per day) during 4.9 years' median follow-up in SHARP; scenario analyses with high-intensity statin regimens (2015 UK

2016 EvidenceUpdates PubMed

14. Usefulness of Nutraceuticals (Armolipid Plus) Versus Ezetimibe and Combination in Statin-Intolerant Patients With Dyslipidemia With Coronary Heart Disease (PubMed)

Usefulness of Nutraceuticals (Armolipid Plus) Versus Ezetimibe and Combination in Statin-Intolerant Patients With Dyslipidemia With Coronary Heart Disease Statins are extensively used to treat dyslipidemia, but, because of their low tolerability profile, they are discontinued in a significant proportion of patients. Ezetimibe and nutraceuticals have been introduced as alternative therapies and have proved to be effective and well tolerated. A single-blind, single-center, randomized, prospective (...) , and parallel group trial comparing a combination of nutraceuticals (red yeast rice, policosanol, berberine, folic acid, coenzyme Q10 and astaxanthin), called Armolipid Plus, and ezetimibe for 3 months in terms of efficacy and tolerability. Patients who did not achieve their therapeutic target (low-density lipoprotein cholesterol <100 mg/dl) could add the alternative treatment on top of randomized treatment for another 12 months: 100 patients who are dyslipidemic with ischemic heart disease treated

2015 EvidenceUpdates

15. Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT (Full text)

Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT Statins lower low-density lipoprotein cholesterol (LDL-C) and high-sensitivity C-reactive protein (hs-CRP); addition of ezetimibe to statins further reduces LDL-C and hs-CRP. An analysis of the relationship between achieved LDL-C and hs-CRP targets and outcomes for simvastatin (...) and ezetimibe/simvastatin was prespecified in Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT).The IMPROVE-IT trial randomly assigned 18 144 patients stabilized after acute coronary syndrome to simvastatin or ezetimibe/simvastatin. LDL-C and hs-CRP were measured at baseline and 1 month after randomization. Outcomes were assessed in those achieving one or both of the prespecified targets of LDL-C<70 mg/dL and hs-CRP<2 mg/L versus achieving neither target, adjusting

2015 EvidenceUpdates PubMed

16. Ezetimibe plus a Statin after Acute Coronary Syndromes. (Full text)

Ezetimibe plus a Statin after Acute Coronary Syndromes. 26444734 2015 10 08 2018 12 02 1533-4406 373 15 2015 10 08 The New England journal of medicine N. Engl. J. Med. Ezetimibe plus a Statin after Acute Coronary Syndromes. 1476-7 10.1056/NEJMc1509363 Cannon Christopher P CP Blazing Michael A MA Braunwald Eugene E eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Anticholesteremic Agents 0 Azetidines 0 Cholesterol, LDL 0 Hydroxymethylglutaryl-CoA Reductase Inhibitors AGG2FN16EV

2015 NEJM PubMed

17. Ezetimibe plus a Statin after Acute Coronary Syndromes. (Full text)

Ezetimibe plus a Statin after Acute Coronary Syndromes. 26444735 2015 10 08 2018 12 02 1533-4406 373 15 2015 10 08 The New England journal of medicine N. Engl. J. Med. Ezetimibe plus a Statin after Acute Coronary Syndromes. 1473 10.1056/NEJMc1509363 Silbernagel Günther G Baumgartner Iris I März Winfried W eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Anticholesteremic Agents 0 Azetidines 0 Cholesterol, LDL 0 Hydroxymethylglutaryl-CoA Reductase Inhibitors AGG2FN16EV

2015 NEJM PubMed

18. Ezetimibe plus a Statin after Acute Coronary Syndromes. (Full text)

Ezetimibe plus a Statin after Acute Coronary Syndromes. 26444736 2015 10 08 2018 12 02 1533-4406 373 15 2015 10 08 The New England journal of medicine N. Engl. J. Med. Ezetimibe plus a Statin after Acute Coronary Syndromes. 1473-4 10.1056/NEJMc1509363 Couture Philippe P Durand Madeleine M Laskine Mikhael M eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Anticholesteremic Agents 0 Azetidines 0 Cholesterol, LDL 0 Hydroxymethylglutaryl-CoA Reductase Inhibitors AGG2FN16EV

2015 NEJM PubMed

19. Ezetimibe plus a Statin after Acute Coronary Syndromes. (Full text)

Ezetimibe plus a Statin after Acute Coronary Syndromes. 26444737 2015 10 08 2018 12 02 1533-4406 373 15 2015 10 08 The New England journal of medicine N. Engl. J. Med. Ezetimibe plus a Statin after Acute Coronary Syndromes. 1474 10.1056/NEJMc1509363 Egom Emmanuel E EE eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Anticholesteremic Agents 0 Azetidines 0 Cholesterol, LDL 0 Hydroxymethylglutaryl-CoA Reductase Inhibitors AGG2FN16EV Simvastatin AIM IM N Engl J Med. 2015 Jun

2015 NEJM PubMed

20. Ezetimibe plus a Statin after Acute Coronary Syndromes. (Full text)

Ezetimibe plus a Statin after Acute Coronary Syndromes. 26444738 2015 10 08 2018 12 02 1533-4406 373 15 2015 10 08 The New England journal of medicine N. Engl. J. Med. Ezetimibe plus a Statin after Acute Coronary Syndromes. 1474-5 10.1056/NEJMc1509363 Patti Giuseppe G Cavallari Ilaria I eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Anticholesteremic Agents 0 Azetidines 0 Cholesterol, LDL 0 Hydroxymethylglutaryl-CoA Reductase Inhibitors AGG2FN16EV Simvastatin AIM IM N Engl J

2015 NEJM PubMed